Two-year efficacy of varenicline tartrate and counselling for inpatient smoking cessation (STOP study): a randomized controlled clinical trial

Kristin V. Carson-Chahhoud*, Brian J. Smith, Matthew J. Peters, Malcolm P. Brinn, Faisal Ameer, Kuljit Singh, Robert Fitridge, John Litt, David Edwards, Simon A. Koblar, Jim Jannes, Antony J. Veale, Sharon Goldsworthy, Khin Hnin, Adrian J. Esterman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)
16 Downloads (Pure)


Introduction Varenicline tartrate is superior for smoking cessation to other tobacco cessation therapies by 52 weeks, in the outpatient setting. We aimed to evaluate the long-term (104 week) efficacy following a standard course of inpatient-initiated varenicline tartrate plus Quitline-counselling compared to Quitline-counselling alone. Methods Adult patients (n = 392, 20–75 years) admitted with a smoking-related illnesses to one of three hospitals, were randomised to receive either 12-weeks of varenicline tartrate (titrated from 0.5mg daily to 1mg twice-daily) plus Quitline-counselling, (n = 196) or Quitline-counselling alone, (n = 196), with continuous abstinence from smoking assessed at 104 weeks. Results A total of 1959 potential participants were screened for eligibility between August 2008 and December 2011. The proportion of participants who remained continuously abstinent (intention-to-treat) at 104 weeks were significantly greater in the varenicline tartrate plus counselling arm (29.2% n = 56) compared to counselling alone (18.8% n = 36; p = 0.02; odds ratio 1.78; 95%CI 1.10 to 2.86, p = 0.02). Twenty-two deaths occurred during the 104 week study (n = 10 for varenicline tartrate plus counselling and n = 12 for Quitline-counselling alone). All of these participants had known or developed underlying co-morbidities. Conclusions This is the first study to examine the efficacy and safety of varenicline tartrate over 104 weeks within any setting. Varenicline tartrate plus Quitline-counselling was found to be an effective opportunistic treatment when initiated for inpatient smokers who had been admitted with tobacco-related disease.

Original languageEnglish
Article numbere0231095
Pages (from-to)1-11
Number of pages11
JournalPLoS ONE
Issue number4
Publication statusPublished - 1 Apr 2020
Externally publishedYes

Bibliographical note

Copyright the Author(s) 2020. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.
A correction exists for this article and can be found in PLoS ONE 16(12): e0262188 at doi: 10.1371/journal.pone.0262188


Dive into the research topics of 'Two-year efficacy of varenicline tartrate and counselling for inpatient smoking cessation (STOP study): a randomized controlled clinical trial'. Together they form a unique fingerprint.

Cite this